
    
      The study was submitted to Health Canada and has received the letter of no objection. A
      randomized, double-blind, placebo-controlled trial will be conducted. The randomization
      scheme will be prepared and done by the pharmacy department at McMaster University. Ninety
      patients undergoing primary hip arthroplasty will be recruited from the preoperative clinic.
      Forty-five patients in each population will be allocated to a gabapentin group and the other
      forty-five patients will be allocated to a placebo group.
    
  